“The effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence,” the study reads . . .
"At this time, we cannot recommend herbal cannabis for arthritis pain management given the lack of efficacy data, potential harm from the drug, and availability of other therapies for managing pain… Physicians should discourage rheumatology patients from using medical marijuana as a therapy” . . .
“Contrary to public belief, inhaled herbal cannabis is not innocuous,” the study reads. “Risks can be categorized as the** immediate effects on cognition, psychomotor function, cardiovascular effects and mood, and the chronic consequences on mental ability, pulmonary function, potential cancer risk and drug dependence.**”
Dr. Fitzcharles is currently an associate professor of medicine in the Division of Rheumatology at McGill University. She received her medical education at University of Cape Town, South Africa, and completed specialist training in rheumatology at The London Hospital, Whitechapel, London, England.
She has been on faculty at McGill University since 1984, and has been a consultant rheumatologist to the McGill Pain Centre, at the Montreal General Hospital for the past five years. Academic activities have included being an examiner for the Royal College of Physicians of Canada Internal Medicine Specialist Examinations for 15 years, a member of Medical Admissions committee for medical students to McGill University for 15 years, and director of postgraduate medical education at Royal Victoria Hospital, and member of postgraduate medical education board of McGill University. In the past 10 years, research interests have been in the area of pain and rheumatic diseases. Publications have been in the area of chronic pain in fibromyalgia, alternative treatments use in rheumatic diseases, and more recently evaluation of the pain experience in rheumatoid arthritis and osteoarthritis. Other research activities include evaluation of new compounds in the management of osteoarthritis, rheumatoid arthritis, psoriatic arthritis and fibromyalgia syndrome.
I bet there will be an almost complete blackout in the U.S. Media about this new medical study.
The citizens of the United States may hear about it in our Media but I am going to guess it will take another 1-3 years for us to be informed.
News Media wants everyone to smoke this garbage so they have a stoned American populace and they can help the government take away more of our freedoms while less and less people are paying attention.